WALNUT CAP (00905) announced a net loss of 172 million Hong Kong dollars for the fiscal year 2025.
Walnut Capital (00905) released its annual performance for the year ending December 31, 2025, with a revenue of HK$1.994 million, an increase of 269.9% year-on-year; a net loss of HK$172 million, compared to a profit of HK$399,000 in the same period last year; basic loss per share of 16.4 HK cents.
WALNUT CAP (00905) announced its financial performance for the year ending December 31, 2025, with a revenue of HK$1.994 million, an increase of 269.9% year-on-year; a net loss of HK$172 million, compared to a profit of HK$399,000 in the same period last year; and a basic loss per share of 16.4 HK cents.
The main reason for the performance turning from profit to loss during the period was due to (i) recognizing impairment losses and losses from selling cryptocurrencies of approximately HK$1.429 billion and HK$7.4 million, respectively; (ii) recognizing a net loss of approximately HK$4.1 million from fair value changes of financial assets accounted for through profit or loss, while recognizing a net gain of approximately HK$17.4 million from fair value changes of financial assets accounted for through profit or loss in the same period.
Related Articles

CHINA RE (01508) released its annual performance, with a net profit attributable to shareholders of 9.771 billion yuan, a decrease of 7.44% year-on-year.

OCUMENSION-B(01477): The first patient has been enrolled in the Phase III clinical trial of OT-211.

CHANGMAO BIO (00954) announced a net loss attributable to shareholders of approximately 66.763 million yuan in 2025, a year-on-year decrease of 2.17%.
CHINA RE (01508) released its annual performance, with a net profit attributable to shareholders of 9.771 billion yuan, a decrease of 7.44% year-on-year.

OCUMENSION-B(01477): The first patient has been enrolled in the Phase III clinical trial of OT-211.

CHANGMAO BIO (00954) announced a net loss attributable to shareholders of approximately 66.763 million yuan in 2025, a year-on-year decrease of 2.17%.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


